Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Abstract Text:

Allen Brinker,Andrew Mosholder,Stephanie D Schech,Margaret Burgess,Mark Avigan,

INTRODUCTION: Published literature suggests that attention-deficit/hyperactivity disorder (ADHD) affects 4% of adults and that as many as 60% of children with a diagnosis of ADHD will continue to have problems with inattention and impulsivity in adulthood. We analyzed cross-sectional prescription claims data and data from a national survey of office-based physicians for further inference on the likelihood of treatment with ADHD medications into adulthood. METHODS: This study used data from a proprietary, national survey of office-based physicians (the IMS Health National Disease and Therapeutic Index, NDTI) to describe the indication associated with office visits with mention of common stimulant medications and atomoxetine. Enrollment and prescription claims data maintained by a large national health-care company were analyzed for age-specific utilization of these same agents. RESULTS: Data from the NDTI suggest that the vast majority of visits associated with a stimulant medication or atomoxetine was coded with a diagnosis consistent with a mental health condition and not obesity/weight loss. The health plans included in this study processed 222,096 prescriptions for stimulant medications and atomoxetine among 43,175 unique patients aged 1-64 years during the calendar year 2004. Analyses of pharmacy claims data showed a steep increase in use through age 11 (prevalence=70.3 per 1,000 covered lives) followed by a marked decrease and plateau from age 25 through age 64 years (prevalence=5 to 10 per 1,000 covered lives). CONCLUSIONS: On the basis of comparison of the prevalence rate peak of 70 per 1,000 around age 11 years to a plateau of 7 per 1,000 during the early career years, our results are consistent with a prediction that at least one child in 10 placed on an ADHD medication in childhood will receive treatment in to adulthood. The decrease in the prevalence of use of these medications with advancing age as seen in this cross-sectional study may reflect upon several clinical and secular factors.

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Publishing Authors By Initials

A Brinker,A Mosholder,SD Schech,M Burgess,M Avigan,

For similar organic chemicals: amines: propylamines research abstracts see: organic chemicals: amines: propylamines research

PUBMED ID PMID:

MEDLINE DATE:

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of child and adolescent psychopharmacology

VOLUME: 17

Page Numbers: 328-33

Journal Abbreviation:

ISSN: 1044-5463

DAY: 3

MONTH: Jun

YEAR: 2007

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9105358

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Keywords Mesh Terms:

KEYWORDS: Propylamines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. Information

Substance Name: atomoxetine

Registry Number: 83015-26-3

Grant and Affiliation Information for Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.

AFFILIATION: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, USA. allen.brinker@fda.hhs.gov

Country: United States

AGENCY: United States FDA

GRANT: FD-U-002067-03

ACRONYM: FD

MEDLINETA: J Child Adolesc Psychopharmaco

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood Related Publications

• An observational study of cholecystectomy in patients receiving tegaserod.
• Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab.
• Cellular immunotherapy for multiple myeloma.
• Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells.
• Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.
• Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.
• Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
• Vaccine therapy and adoptive immunotherapy in hematologic malignancies.